AU2014352801B2 - Compositions for the treatment of rheumatoid arthritis and methods of using same - Google Patents

Compositions for the treatment of rheumatoid arthritis and methods of using same Download PDF

Info

Publication number
AU2014352801B2
AU2014352801B2 AU2014352801A AU2014352801A AU2014352801B2 AU 2014352801 B2 AU2014352801 B2 AU 2014352801B2 AU 2014352801 A AU2014352801 A AU 2014352801A AU 2014352801 A AU2014352801 A AU 2014352801A AU 2014352801 B2 AU2014352801 B2 AU 2014352801B2
Authority
AU
Australia
Prior art keywords
weeks
sarilumab
treatment
subject
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014352801A
Other languages
English (en)
Other versions
AU2014352801A1 (en
Inventor
Chungpeng FAN
Stefano FIORE
Mark Genovese
Xiaohong Huang
Martine JASSON
Vanessa MARKS
Allen Radin
Janet VAN ADELSBERG
Hubert VAN HOOGSTRATEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2014352801A1 publication Critical patent/AU2014352801A1/en
Application granted granted Critical
Publication of AU2014352801B2 publication Critical patent/AU2014352801B2/en
Priority to AU2020223706A priority Critical patent/AU2020223706B2/en
Priority to AU2024204881A priority patent/AU2024204881A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014352801A 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same Active AU2014352801B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020223706A AU2020223706B2 (en) 2013-11-22 2020-08-26 Compositions for the treatment of rheumatoid arthritis and methods of using same
AU2024204881A AU2024204881A1 (en) 2013-11-22 2024-07-16 Compositions for the treatment of rheumatoid arthritis and methods of using same

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US61/907,796 2013-11-22
US201462008787P 2014-06-06 2014-06-06
US62/008,787 2014-06-06
EP14306366.7 2014-09-05
EP14306366 2014-09-05
PCT/US2014/066856 WO2015077582A1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020223706A Division AU2020223706B2 (en) 2013-11-22 2020-08-26 Compositions for the treatment of rheumatoid arthritis and methods of using same

Publications (2)

Publication Number Publication Date
AU2014352801A1 AU2014352801A1 (en) 2016-06-23
AU2014352801B2 true AU2014352801B2 (en) 2020-05-28

Family

ID=51518724

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014352801A Active AU2014352801B2 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same
AU2020223706A Active AU2020223706B2 (en) 2013-11-22 2020-08-26 Compositions for the treatment of rheumatoid arthritis and methods of using same
AU2024204881A Pending AU2024204881A1 (en) 2013-11-22 2024-07-16 Compositions for the treatment of rheumatoid arthritis and methods of using same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020223706A Active AU2020223706B2 (en) 2013-11-22 2020-08-26 Compositions for the treatment of rheumatoid arthritis and methods of using same
AU2024204881A Pending AU2024204881A1 (en) 2013-11-22 2024-07-16 Compositions for the treatment of rheumatoid arthritis and methods of using same

Country Status (11)

Country Link
US (1) US20160280782A1 (enExample)
EP (2) EP3071230B1 (enExample)
JP (4) JP6657089B2 (enExample)
KR (4) KR20230155586A (enExample)
CN (2) CN106413748A (enExample)
AU (3) AU2014352801B2 (enExample)
CA (1) CA2930615C (enExample)
MX (2) MX377190B (enExample)
PL (1) PL3071230T3 (enExample)
SG (1) SG10201804000TA (enExample)
WO (1) WO2015077582A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
KR20230155586A (ko) * 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
KR20230093522A (ko) * 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
KR102871642B1 (ko) 2017-12-07 2025-10-15 자크로스 가부시키가이샤 포트가 부착된 백 및 캡이 부착된 백
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
JP7542543B2 (ja) * 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2022545312A (ja) * 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대
US12254347B2 (en) * 2021-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Data pipeline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053751A1 (en) * 2011-10-11 2013-04-18 Sanofi Compositions for the treatment of rheumatoid arthritis and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PT3071230T (pt) * 2013-11-22 2020-06-26 Regeneron Pharma Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
KR20230155586A (ko) * 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053751A1 (en) * 2011-10-11 2013-04-18 Sanofi Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
KR20260060447A (ko) 2026-05-04
PL3071230T3 (pl) 2020-09-21
EP3770173A1 (en) 2021-01-27
MX2020011993A (es) 2021-01-29
CA2930615C (en) 2023-04-04
AU2024204881A1 (en) 2024-08-15
JP2022033891A (ja) 2022-03-02
MX377190B (es) 2025-03-07
KR20230155586A (ko) 2023-11-10
WO2015077582A1 (en) 2015-05-28
KR20160079121A (ko) 2016-07-05
AU2014352801A1 (en) 2016-06-23
JP2024026223A (ja) 2024-02-28
JP6657089B2 (ja) 2020-03-04
EP3071230B1 (en) 2020-04-08
MX2016006595A (es) 2016-09-06
CN106413748A (zh) 2017-02-15
JP2016539125A (ja) 2016-12-15
JP2026032035A (ja) 2026-02-25
AU2020223706B2 (en) 2024-04-18
SG10201804000TA (en) 2018-07-30
KR20220056254A (ko) 2022-05-04
US20160280782A1 (en) 2016-09-29
EP3071230A1 (en) 2016-09-28
CA2930615A1 (en) 2015-05-28
CN120514847A (zh) 2025-08-22
AU2020223706A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
AU2020223706B2 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
US20260027202A1 (en) Treatment of rheumatoid arthritis with an il-6r antibody
US9943594B2 (en) Methods for the treatment of rheumatoid arthritis
JP2020045351A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
HK40044249A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
HK1225635B (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
IL265949A (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
HK1195495B (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same
HK1195495A (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)